Diploid Genomics, Inc., also known as DGI, an AI-driven genomics analytics company, has officially launched in partnership with Healthier Capital, a leading health-tech venture capital firm. The company is spearheaded by genomics pioneer J. Craig Venter, Ph.D., and aims to transform the discovery and diagnosis of complex and life-threatening diseases. DGI combines advanced genomic sequencing, AI modeling, imaging, and health data to provide precise diagnostic insights for researchers, life sciences companies, healthcare systems, and patients, enabling more predictable and actionable health outcomes.
Health Technology Insights: MHK Launches SmartProminence AI Solutions
Aman Mahajan, M.D., Ph.D., partner at Healthier Capital, expressed excitement about co-founding DGI alongside Venter and the leadership team, emphasizing the potential for transformative improvements in disease prevention, diagnosis, treatment, and healthcare innovation. Amir Dan Rubin, founder and managing partner of Healthier Capital, highlighted that DGI’s proprietary AI-driven approach integrates genomic sequencing with imaging and other data streams to change the way therapies are developed, diseases are detected, and patient care is delivered.
Health Technology Insights: Artera Secures $65Million Growth Investment and Reaches $100Million CARR
From its inception, DGI has been built as a high-performance platform with access to the latest sequencing technologies from PacBio and Oxford Nanopore, specialized computing infrastructure, and proprietary genomics and imaging datasets from the J. Craig Venter Institute. The company is pursuing strategic collaborations with academic medical centers, AI research organizations, and life sciences companies to maximize its technological and clinical impact. DGI is also establishing its own sequencing center in San Diego, which will seek CLIA certification to offer clinical-grade AI-enhanced sequencing.
The company is led by Dr. Venter, multimodal imaging expert Anders Dale, Ph.D., and computational sciences specialist Gene Myers, Ph.D. Dr. Venter is the founder of the J. Craig Venter Institute and its predecessor, The Institute for Genomic Research, where he and his team sequenced the first free-living organism and numerous microbial genomes. He also founded Celera Genomics, which competed to sequence the first human genome, an achievement announced at the White House by President Bill Clinton, as well as Synthetic Genomics, SGI-DNA, and Human Longevity, Inc.
Dr. Dale, president of JCVI and professor emeritus at UC San Diego, has dedicated his career to developing advanced imaging techniques and integrating imaging with genomics to predict health outcomes. He also founded several AI-driven startups. Gene Myers, Ph.D., formerly vice president of informatics research at Celera Genomics and a former faculty member at UC Berkeley, is known for creating the BLAST bioinformatics tool and the paired-end whole genome shotgun sequencing protocol used to sequence the fly, human, and mouse genomes in three years.
Healthier Capital participated as co-founder and sole external investor in DGI’s Series Seed round, which closed in January. The initial equity holders include the company’s founders and JCVI. Gibson, Dunn & Crutcher LLP served as legal counsel. Dr. Venter stated that Healthier Capital’s deep experience in healthcare delivery, scientific research, and health-tech networks will help DGI achieve its mission and realize the full potential of genomics in transforming healthcare.
Health Technology Insights: First Stop Health Joins ParetoHealth Network
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
